Regulation of Endoplasmic Reticulum Stress by Empagliflozin in Doxorubicin‐Induced Cardiotoxicity in Rats
Journal of Cellular and Molecular Medicine · 2026-05 · 30 (9)
DOI: 10.1111/jcmm.71161 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 29.04.2026. Verfasst von Akshi Malik und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre, Winnipeg, Canada. Hauptthemen laut MEDLINE: Doxorubicin, Benzhydryl Compounds, Cardiotoxicity, Endoplasmic Reticulum Stress. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Heart and Stroke Foundation of Canada, St. Boniface Hospital Foundation., Molson Women's Heart Health Program.
Abstract (Originalsprache)
Although Doxorubicin (Dox) is an effective anticancer drug, it can cause severe cardiotoxicity. While several mechanisms have been proposed to explain Dox‐induced cardiomyopathy (DIC), strategies to prevent it remain limited. In previous research on isolated cardiomyocytes, we identified that Empagliflozin (EMPA), an antidiabetic drug, mitigated Dox‐induced ER stress and apoptosis. In this in vivo study using rats, we further investigated EMPA's potential in preventing and treating DIC. Rats administered a cumulative dose of 15 mg/kg Dox exhibited significant cardiovascular damage, including left ventricular cavity dilation, decreased left ventricular ejection fraction (LVEF), ER dilation, mitochondrial defects and vacuole formation. These structural changes were linked to the activation of ER‐stress pathways (PERK, IRE1 and ATF6) and upregulation of apoptotic proteins initiated by ER stress. When EMPA (10 mg/kg/day) was administered either prophylactically or concurrently with Dox, it significantly attenuated adverse LV remodelling and preserved LVEF. Additionally, EMPA prevented ER stress and subsequent apoptosis in the myocardium of the Dox + EMPA‐treated group. These findings suggest that EMPA offers cardioprotective benefits in DIC, likely through the inhibition of ER‐stress‐induced myocardial injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre, Winnipeg, Canada.
- Department of Physiology and Pathophysiology, University of Manitoba, Winnipeg, Canada.
- Section of Hematology and Oncology, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.
- Paul Albrechtsen Research Institute, CancerCare Manitoba, Winnipeg, Canada.
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Section of Cardiology, Department of Internal Medicine, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.
Förderung
- Heart and Stroke Foundation of Canada
- St. Boniface Hospital Foundation.
- Molson Women's Heart Health Program
Zitieren
APA
Malik, A., Cheung, D. C. Y., Ledingham, D. A., Desautels, D., Herrmann, J., Singal, P. K., & Jassal, D. S. (2026). Regulation of Endoplasmic Reticulum Stress by Empagliflozin in Doxorubicin‐Induced Cardiotoxicity in Rats. Journal of Cellular and Molecular Medicine, 30(9). https://doi.org/10.1111/jcmm.71161
Vancouver
Malik A, Cheung DCY, Ledingham DA, Desautels D, Herrmann J, Singal PK, et al. Regulation of Endoplasmic Reticulum Stress by Empagliflozin in Doxorubicin‐Induced Cardiotoxicity in Rats. Journal of Cellular and Molecular Medicine. 2026;30(9). doi:10.1111/jcmm.71161
BibTeX
@article{Malik2026,
author = {Malik, Akshi and Cheung, David C Y and Ledingham, D Allison and Desautels, Danielle and Herrmann, Joerg and Singal, Pawan K and Jassal, Davinder S},
title = {Regulation of Endoplasmic Reticulum Stress by Empagliflozin in Doxorubicin‐Induced Cardiotoxicity in Rats},
journal = {Journal of Cellular and Molecular Medicine},
year = {2026},
volume = {30},
number = {9},
doi = {10.1111/jcmm.71161}
}
EUVIMED